Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Hormonal Regulation01:33

Hormonal Regulation

36.3K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.8K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.8K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.4K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.4K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

6.6K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

The New England journal of medicine·2026
Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026
Same author

Failure of endocytic flux in Donnai-Barrow syndrome caused by LRP2 p.C1400R.

JCI insight·2026
Same author

Proximity Labeling Reveals How Lrp2 Interacts with the Endocytic Machine.

Journal of proteome research·2026
Same author

Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same journal

Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Timing Matters: Effects of Early and Late Estrogen Replacement Therapy on Glucose Metabolism and Vascular Reactivity in Ovariectomized Aged Wistar Rats.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Genetic Variants Associated with High Susceptibility of Premature Ischemic Stroke.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
See all related articles

Related Experiment Video

Updated: Feb 21, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.0K

Aldosterone breakthrough does not alter central hemodynamics.

Andrew Beenken1, Andrew S Bomback1

  • 1Department of Medicine, Division of Nephrology, Columbia University Medical Center, New York, NY, USA.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|October 11, 2017
PubMed
Summary
This summary is machine-generated.

Aldosterone breakthrough, a common issue in heart and kidney disease treatments, does not affect central blood pressure. Its impact may stem from non-genomic effects, not fluid regulation.

Keywords:
Angiotensin-converting enzyme inhibitoraldosterone breakthroughangiotensin receptor blockeraugmentation indexaugmentation pressurecentral blood pressurecentral pulse pressure

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

778

Related Experiment Videos

Last Updated: Feb 21, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

778

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are crucial for managing heart failure and kidney disease.
  • Aldosterone breakthrough, where aldosterone levels rise after 6-12 months of ACEI/ARB therapy, affects up to 40% of patients.
  • The pathophysiology of aldosterone breakthrough and its effect on central blood pressure remain unclear.

Purpose of the Study:

  • To investigate the relationship between aldosterone breakthrough and central blood pressure in patients on ACEIs/ARBs.
  • To determine if aldosterone breakthrough influences central hemodynamic parameters.

Main Methods:

  • Nineteen patients with controlled peripheral blood pressure on stable ACEI/ARB doses were enrolled.
  • Aldosterone levels and central blood pressure parameters were measured using the SphygmoCor system.
  • Patients were categorized into 'breakthrough' (aldosterone >15 ng/dl) and 'no breakthrough' groups for comparison.

Main Results:

  • Six patients experienced aldosterone breakthrough (mean aldosterone 33.8 ng/dl), while 13 did not (mean aldosterone 7.1 ng/dl).
  • No significant differences were observed in any central blood pressure parameters between the groups.
  • Peripheral blood pressure was well-controlled in all subjects.

Conclusions:

  • Aldosterone breakthrough is not correlated with changes in central blood pressure.
  • The clinical significance of aldosterone breakthrough may be linked to its pro-fibrotic and pro-inflammatory actions.
  • Future research should focus on the non-genomic effects of aldosterone in disease progression.